FDA Pledges 10% Reduction In NDA Review Time As Part Of “Strategic Plan”
FDA plans to deliver a two-month reduction in review times for standard new molecular entity NDA filings as one "benchmark" for the agency's "strategic plan.
FDA plans to deliver a two-month reduction in review times for standard new molecular entity NDA filings as one "benchmark" for the agency's "strategic plan.